DARÉ BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2953 USD | +5.46% |
|
-38.49% | -4.43% |
| Mar. 28 | Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 28 | Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 5.43M | Sales 2025 * | 33.37M | Capitalization | 29.7M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M | Net income 2025 * | -7M | EV / Sales 2024 * | 5.47 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.89 x |
| P/E ratio 2024 * |
-1.09
x | P/E ratio 2025 * |
-4.92
x | Employees | 25 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daré Bioscience, Inc.
More recommendations
More press releases
| 1 day | +5.46% | ||
| 1 week | -38.49% | ||
| Current month | -39.76% | ||
| 1 month | -38.27% | ||
| 3 months | -5.11% | ||
| 6 months | -36.29% | ||
| Current year | -4.43% |
1 week
0.28
0.48
1 month
0.280.56
Current year
0.280.59
1 year
0.271.10
3 years
0.272.51
5 years
0.273.85
10 years
0.276.62
| Managers | Title | Age | Since |
|---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 14-12-31 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 14-12-31 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 19-11-19 |
| Chairman | 75 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.2953 | +5.46% | 165,190 |
| 24-04-19 | 0.28 | -5.12% | 555,803 |
| 24-04-18 | 0.2951 | +4.39% | 975,780 |
| 24-04-17 | 0.2827 | -41.70% | 4,261,291 |
| 24-04-16 | 0.4849 | +1.00% | 95,336 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.2953
USD
Average target price
4
USD
Spread / Average Target
+1,254.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.43% | 29.7M | |
| -0.02% | 42.11B | |
| +48.54% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- DARE Stock
